You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金丨開源證券:國邦醫藥估值性價比高,維持“買入”評級
格隆匯 08-01 13:51
開源證券研報指出,國邦醫藥2025Q2業績超預期,動保板塊迎來大幅增長。2025上半年公司動保板塊收入12.59億元(+70.37%);動保業務規模優勢帶來的邊際成本下降明顯體現,2025上半年氟苯尼考出貨量突破2000噸,市佔率持續提升;鹽酸多西環素獲批CEP證書,銷售國家突破50個,客户超200家。2025上半年公司境外收入12.91億元(+0.23%)。另外,公司與蘭州大學天然產物全國重點實驗室合作成立健康活性物質研發與應用中心,對標國際水平開展小分子新藥物研發;與浙江大學創新創業研究院達成戰略合作,併成立股權投資基金,重點投資前沿生物醫藥、新興科技產業等領域。當前股價對應PE為13.3/10.7/9.5倍,估值性價比高,維持“買入”評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account